ClinicalTrials.gg
RecruitingNCT05903859Updated Mar 2, 2026

Improvement of Reproductive Function in Men With Spinal Cord Injury (SCI)

A Phase 3 interventional study of Probenecid 500 Milligrams (mg) and probenecid 250 Milligrams (mg) in Infertility, Male, sponsored by University of Miami. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by University of Miami · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Infertility, Male with a site in United States — 12 open to participants now, 16 under way, 1 of them phase 3. Infertility, Male · United States.

Planned enrollment
11th of 36
90 · median 58
Started
2024
with 2 others
Phase 3
3 of 58
1 open now
Primary completion
2027-05
later than 9 of 15 live
Registered
49th of 58
by date

Among the 58 studies in Infertility, Male with a site in United States, this one is the 11th largest by planned enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2024, is one of 3 in phase 3, reaches primary completion later than 9 of the 15 other live ones, and was the 49th registered.

Infertility, Male

283 studies on the registry are indexed under Infertility, Male; 65 are open to participants now.

Browse Infertility, Male studies →

Open to participants now

12 of the 58 studies in Infertility, Male with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Infertility, Male studies recruiting now, 17 (41%) set no upper age limit and 24 (59%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Infertility, Male with a site in United States, or all of them as a file.
02

Study summary

This is a study of infertility which often occurs in men with spinal cord injury. Most men with spinal cord injury have a normal sperm count but abnormally low sperm motility - which means that the sperm does not swim well. This study will determine if a medicine given by mouth will improve sperm motility in men with spinal cord injuries. The medicine is called probenecid.

03

Conditions studied

  • Infertility, Male

Keywords

  • Spinal cord injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has a traumatic spinal cord injury.
  2. Subject is male and is 18 years or older.

Exclusion criteria

Exclusion Criteria:

  1. Subject has been injured less than 1 year.
  2. The subject is known to be azoospermic.
  3. The subject has an indwelling urethral Foley catheter.
  4. Subject is under the age of 18 years.
  5. Subject has an unstable medical condition including, but not limited to, Crohn's disease, ulcerative colitis, colon cancer or has other conditions deemed to be exclusionary per the Investigator.
  6. Subject is unable to consent or comprehend the procedures and their implications.
  7. Subject has a permanent implanted electrical device, i.e., cardiac pacemaker, phrenic nerve stimulator, spinal cord stimulator, etc.
  8. Any subject for whom the procedure or medication is otherwise .
  9. Subject has to probenecid.
  10. Subject has a history of uric acid kidney stones and/or peptic ulcer.
  11. The subject has had a febrile Urinary Tract Infection (UTI) within the 2 months prior to enrollment.
  12. The subject is taking methotrexate, aspirin, other salicylates, or anti-inflammatory medicines.
  13. The subject has a history of Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Full dose group

    Participants in this group will receive the full dose of probenecid for a total of 90 days.

    Drug: Probenecid 500 Milligrams (mg)

  • Experimental
    Half dose group

    Participants in this group will receive half the dose of probenecid for a total of 90 days.

    Drug: probenecid 250 Milligrams (mg)

  • Placebo comparator
    Control-placebo group

    Participants in this group will receive a placebo dose (No active ingredient) for a total of 90 days.

    Drug: Placebo

Interventions

  • DrugProbenecid 500 Milligrams (mg)

    Participants in this group will receive 500 mg of probenecid by mouth twice a day for a total of 90 days.

  • Drugprobenecid 250 Milligrams (mg)

    Participants in this group will receive 250 mg of probenecid by mouth twice a day for a total of 90 days.

  • DrugPlacebo

    Participants in this group will receive a placebo pill by mouth twice a day for a total of 90 days.

06

What researchers measure

Primary outcomes

  1. Change in total motile sperm count

    The total sperm count will be assessed by calculating semen volume times sperm count times sperm motility percentage.The unit of measurement is in Millions.

    Time frame: Baseline, up to 6 months post intervention, up to 6 months post follow up.

Secondary outcomes

  1. Change in percentage sperm DNA fragmentation

    The percentage of DNA fragmented sperm in specimen

    Time frame: Baseline, up to 6 months post intervention, up to 6 months post follow up.

  2. Change in percentage of sperm viability

    The percentage of viable sperm ion specimen

    Time frame: Baseline, up to 6 months post intervention, up to 6 months post follow up.

  3. Change in semen inflammasome markers

    Markers will be measured in picogram/milliliter units

    Time frame: Baseline, up to 6 months post intervention, up to 6 months post follow up.

  4. Number of treatment-related adverse events

    Treatment-related adverse events will be assessed by the treating physician using Common Terminology Criteria for Adverse Events 4 (CTCAE 4)

    Time frame: Up to 6 months post follow up.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ibrahim E, Aballa TC, Lynne CM, Brackett NL. Oral probenecid improves sperm motility in men with spinal cord injury. J Spinal Cord Med. 2018 Sep;41(5):567-570. doi: 10.1080/10790268.2017.1320875. Epub 2017 May 2. PubMed 28464732 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for May 2027, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2023
First posted
Jun 15, 2023
StartActual
Jan 18, 2024
Primary completionEst.
May 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05903859
Collaborators
Congressionally Directed Medical Research Programs
Responsible party
Emad Ibrahim (Associate Professor, University of Miami) — Principal investigator
First posted
Jun 15, 2023
Start date
Jan 18, 2024
Primary completion
May 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Mar 2, 2026

Study contacts

Odaro Ugbo, BSc
Contact
oxu32@miami.edu
305-243-1491
Orrey Padilla
Contact
oxp210@med.miami.edu
305-243-1491
Emad Ibrahim, MD
principal investigator · University of Miami

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion